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Misfolding is an inherent and potentially problematic propensity of proteins. Misfolded proteins
tend to aggregate and the deposition of aggregated proteins is associated with a variety of highly
debilitating diseases known as amyloidoses. Protein misfolding and aggregation is also increasingly
recognized as the underlying cause of other health problems, including atherosclerosis and immu-
nogenicity of biopharmaceuticals. This raises the question how nature deals with the removal of
obsolete proteins in order to avoid their accumulation and disease. In recent years two proteases,
tPA and factor XII, have been identiﬁed that speciﬁcally recognize aggregates of misfolded proteins.
We here review these discoveries that have uncovered new roles for the ﬁbrinolytic system and the
contact activation system beyond haemostasis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Causes, appearances and consequences of protein misfolding
To fulﬁl their speciﬁc function proteins typically fold into an
ensemble of closely related three-dimensional structures. This na-
tive state is however not stable and all proteins lose eventually
their unique shape (i.e. become ‘‘partially unfolded” or ‘‘partially
denatured”). This is an inherent property of proteins. Of particular
importance in respect to ﬁndings reviewed herein is the fact that
proteins unfold and show characteristics of misfolding upon direct
contact with ‘denaturing’ compounds and materials. Such com-
pounds include glass, lipids, metals and sugar polymers. Strikingly,
a number of these ‘denaturing’ materials are also known to activate
the contact system of blood coagulation and/or induce inﬂamma-
tion (see below). As a consequence misfolded proteins can lose
their biological function. More problematic is the fact that mis-
folded proteins tend to aggregate, which is associated with the
pathology of certain diseases. The propensity of proteins to aggre-
gate varies [1,2] and many environmental conditions can acceler-
ate the aggregation process. Examples include temperature, pH,
oxidative stress, ﬂow stress and glycation as a consequence of
hyperglycemia [3]. As outlined in more detail in other reviews in
this issue one speciﬁc type of aggregation is the formation of ﬁbrils,
termed amyloid [4–6]. The structure of the ﬁbrils that are formedchemical Societies. Published by E
nces B.V., Padualaan 8, 3584
. Gebbink).by the different proteins is similar [7]. They display a common
structural feature: the amyloid cross-b structure, which is charac-
terized by an organized stacking of b-sheets in the ﬁbrils [8].
Besides the formation of ﬁbrils, protein misfolding can result in a
wide variety of aggregates with various different structural appear-
ances, including intermediates (oligomers) of ﬁbrils and unordered
amorphous aggregates of various sizes. For more detailed informa-
tion on the formation of aggregates and amyloid ﬁbrils the reader
is referred to excellent reviews [2,9]. It has been demonstrated that
irrespective of the amino acid sequence oligomeric intermediates
which precede amyloid ﬁbril formation do share structural and
functional properties, which are absent in native proteins [10,11].
Due to the nature or size of these aggregates the presence of
cross-b structure in these protein aggregates cannot always be
conﬁrmed by X-ray diffraction, but they show other hallmarks of
amyloid, such as an increased content of b-sheets, afﬁnity for dyes
such thioﬂavin T and Congo red. Also, amyloid ﬁbrils are detergent
and protease resistant. The term ‘‘amyloid-like” properties is often
used to indicate the presence of characteristics of amyloid in other
aggregates than ﬁbrils. Thus, although aggregates are heteroge-
neous, they possess common non-native structural and functional
properties. The exact details of these common structural aspects
remain to be elucidated.
For a long time it is known that the formation of amyloid is
associated with many human diseases, known as amyloidoses.
Examples include Alzheimer’s disease and dialysis-related amyloi-
dosis (for more information see [3,9] and in this issue). However,lsevier B.V. All rights reserved.
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enon it can be anticipated that misfolding and aggregation can
underlie or contribute to other pathologies that are not yet identi-
ﬁed as protein misfolding disorders. Such health problems may in-
clude atherosclerosis [12], cardiac disease [13] and auto-immune
disorders, such as those associated with the use of biopharmaceu-
ticals [14,15]. Thus, if all proteins can form hazardous species upon
their unfolding, what has nature found to solve this problem? In-
side cells non-native proteins are recognized by chaperones and
targeted for refolding or proteolytic degradation. Although quality
control in the extracellular environment has been postulated [16],
it is largely unknown how accumulation of protein aggregation is
prevented outside cells. In recent years, two homologous serine
proteases, tPA and factor XII (FXII), were identiﬁed that recognize
misfolded proteins, but not their native precursors [17,18], sug-
gesting that the ﬁbrinolytic system and the contact system play a
role in the detection and clearance of misfolded proteins.
2. Haemostasis and the two routes of inducing coagulation
Haemostasis is the prevention of blood loss as a result of injury
and the coagulation of blood is the protective mechanism.
Coagulation results in the formation of a blood clot (thrombus)
that contains a network of polymerized ﬁbrin with aggregated
platelets. In the classical coagulation model, described in 1964 by
both Macfarlane [19] and by Davie and Ratnoff [20], coagulation
is a proteolytic cascade that can be triggered by two converging
enzymatic pathways, termed the extrinsic pathway and the intrin-
sic pathway (Fig. 1, panel a). Coagulation via the extrinsic pathway
is initiated by tissue factor (TF), a transmembrane protein exposed
on the injured vessel wall, that binds coagulation factor VII(a). The
complex of activated factor VIIa (FVIIa) and TF activates factor X.
The intrinsic pathway (all factors required for clotting are present
within blood plasma) is activated in vitro when blood comes in
contact with a negatively charged (anionic) surface such as glassa b
Fig. 1. Classical scheme of the haemostatic systems with the new insights. The format
coagulation. (a) The extrinsic route is started upon injury by exposure of tissue factor (TF)
induced (‘contact activated’) when blood contacts an ‘artiﬁcial’ (anionic) surface, such as
of contact activation of the intrinsic system in physiological clotting has not been esta
proposed in which XI is activated by IIa (activated thrombin). (c) The contact system als
upon cleavage of prekallikrein (PK) and when high molecular weight kininogen (HK) is cl
loop results in the formation of bFXIIa, which in contrast to aFXIIa is not able to activate F
(Plm) which degrades ﬁbrin polymers into ﬁbrin degradation products (FDPs). Plasm
plasminogen activator (tPA) cleaves the zymogen plasminogen (Plg). tPA is also activated
proteins (see text). Proteases are depicted in green.(Fig. 1, panel b). This results in the activation of the so called con-
tact system which consists of the zymogens factor XII, factor XI,
and prekallikrein (PK) and the non-enzymatic cofactor high molec-
ular weight kininogen (HK). Factor XII binds to the ‘‘surface” and
becomes activated. Activated factor XII leads to the propagation
of the intrinsic pathway by the activation of factor XI with forma-
tion of ﬁbrin as its ﬁnal consequence. Deﬁciencies of factors in this
cascade (such as factor VIII, factor IX and factor XI) lead to bleeding
disorders. This shows that the lower part of the intrinsic pathway
of coagulation contributes to physiological haemostasis. Paradoxi-
cally, deﬁciencies in the primary contact factors factor XII, PK or
HK, which activate the intrinsic pathway in vitro, are not associ-
ated with a bleeding phenotype. This suggests that these three fac-
tors do not contribute to this physiological role of the intrinsic
pathway. This contradiction was explained after the identiﬁcation
of an alternative route of activation of factor XI: thrombin, gener-
ated by the extrinsic pathway activates FXI even in the absence
of a negatively charged surface [21–24] (Fig. 1, panel a). The dis-
covery that factor XI is activated in a factor XII-independent man-
ner adds to our understanding of the intrinsic pathway of
coagulation but still leaves factor XII without a physiological
function.
Over the years, next to glass, numerous other materials were
found to induce coagulation of plasma, such as the clay-like mate-
rials kaolin [25], metals, polymer sugar, dextran sulfate DXS [26–
29], sulphatide [30] and ellagic acid [31]. Also more physiologically
relevant ‘‘surfaces” have been shown to activate the contact system
and include endothelial cell-associated glycosaminoglycans, cer-
tain nucleic acids such as extracellular RNA [32], polyphosphates
[33], and also aggregated amyloid b peptide [34–36]. However,
why the contact system responds to this wide variety of materials
is unclear. Thus, and in addition to its paradoxical role in coagula-
tion, the fact that a clear physiological activator of factor XII re-
mained also unclear, made the real biological role of the contact
system even more mysterious.c d
ion of a blood clot by coagulation involves the extrinsic and the intrinsic route of
on the injured blood vessel to VII. (b) Historically the intrinsic route was found to be
a blood container, which leads to activation of factor XII into aFXIIa. However, a role
blished and a role for the intrinsic system in the ampliﬁcation of coagulation was
o leads to the formation of an inﬂammatory response when kallikrein (K) is formed
eaved into the vasoactive non-apeptide bradykinin (BK). In this process, a feed-back
XI into FXIa. (d) The dissolution of a blood clot (ﬁbrinolysis) is mediated by plasmin
in (Plm) is formed by the ﬁbrinolytic system, when ﬁbrin-activated tissue-type
by misfolded protein aggregates. Moreover ﬁbrin has properties similar to misfolded
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Activation of factor XII upon contact with an ‘activating surface’
results not only in the activation of the intrinsic pathway of coag-
ulation but also in the activation of the kallikrein–kinin system by
activation of prekallikrein into kallikrein, leading to an inﬂamma-
tory response [37,38]. Kallikrein has several functions, but most
notably, it cleaves the potent vasoactive proinﬂammatory
nona-peptide bradykinin from high molecular weight kininogen
(HK). Hence, the name kallikrein–kinin system for this pathway.
Kallikrein can cleave factor XII(a), resulting in a positive feed-back
loop. A ﬁrst cleavage causes (surface-bound) factor XII to become
factor XIIa (aFXIIa), the second cleavage causes dissociation of
the light-chain of factor XII, containing the protease domain. Nota-
bly, this fragment of factor XII, known as bFXIIa (or factor XIIf), can
activate the kallikrein–kinin system, but not coagulation, in the
absence of a surface [39] (Fig. 1). Thus, two very distinct enzymatic
systems are triggered by active factor XII; one leading to coagula-
tion (in vitro), the other to an inﬂammatory response.
Kallikrein and bradykinin have a number of roles. First, bradyki-
nin is a potent vasoactive peptide that mediates classical parame-
ters of inﬂammation, such as redness, fever, swelling, blood
pressure and pain. The peptide acts through two G-protein coupled
receptors, B1 and B2, that are present on a large number of cell
types, but most notably endothelial cells (EC). Activation of the
receptors has a role in recruitment of leukocytes and results also
in the secretion of a number of proinﬂammatory and chemotactic
cytokines [40]. Secondly, tissue-type plasminogen activator (tPA)
is released by bradykinin stimulated endothelial cells [41–43]. This
indicates an interplay between the kallikrein–kinin system acti-
vated by factor XII and the ﬁbrinolytic system activated by tPA
(see below) and a role for bradykinin formation in the activation
of proteases necessary for remodeling of the extracellular matrix,
a process necessary for homeostasis. Thirdly, the contact system
can interact with the complement system: activated factor XII
(bFXIIa) is able to activate the complement system [44–46]. The
complement system is another proteolytic cascade system in blood
involved in host defense reactions, such as protection against bac-
terial pathogens (for review on ﬁbrinolysis, coagulation and com-
plement see [47]). Although most of the known roles of the
kallikrein–kinin system are unrelated to coagulation, genetic dele-
tion of both the kininogen gene and the bradykinin B2 receptor
gene in mice protects against thrombosis [48,49]. But in contrast,
patient studies show that levels of kallikrein and bradykinin in-
crease after myocardial infarction, which correlates to their sur-
vival rates [50]. The kallikrein–kinin system is also shown to be
neuroprotective in rat models of ischemic stroke [51,52]. Also B2
receptor knockout mice display exacerbated post-ischemic brain
injury in a similar model [53]. In conclusion, the activities of the
kallikrein–kinin system are diverse, but its role is likely protective
under physiological conditions in order to preserve or restore
homeostasis, although the system may become detrimental under
pathological circumstances, as discussed in the next paragraph.4. Involvement of the contact system in disease
Given the discovery of factor XII as inducer of coagulation
in vitro, there has been special attention for its role in thrombotic
disease. As discussed earlier, and in contrast to its pro-coagulant
activity in vitro, the kallikrein–kinin system has protective proper-
ties in myocardial infarction and heart failure [54]. As part of an
all-cause mortality study an inverse correlation was found be-
tween the levels of factor XII and the risk of cardiovascular disease
[55]. Similarly, lower factor XII levels were found in patients with
coronary heart disease.Hereditary angioedema (HAE) is a life-threatening afﬂiction
caused by uncontrolled generation of bradykinin, that results in
episodes of swelling in various tissues. The episodes can be trig-
gered by allergy attacks and tissue trauma, but often the cause of
an episode remains unknown. Type III HAE is caused by one of
two known rare mutations in factor XII, that lead to increased fac-
tor XII activity [56]. The same pathology, HAE type I or II, is caused
by deﬁciency or dysfunction of C1-inh, the main inhibitor of the
protease activity of factor XII. The induction of blisters in the skin
of HAE type I and II patients is accompanied by generation of kal-
likrein in the blister ﬂuid [57].
There are many other diseases, in which the kallikrein–kinin
system has been implicated, independent of its role as inducer of
coagulation [58]. These pathologies include chronic renal failure
[59], proliferative diabetic retinopathy [60], Alzheimer’s disease
(AD) [34,61], arthritis [62–64], vasculitis [65,66], bowel disease
[64], infection and septic shock [67,68], allergy [69,70], schizophre-
nia [71], preeclampsia [72], recurrent pregnancy loss [73–76] and
cancer [77] and the majority of them have an inﬂammatory com-
ponent. Whether activation in all these conditions is protective
or detrimental remains to be established, but an intriguing ques-
tion that arises is why and how the contact system becomes acti-
vated, especially since the presence of contact-activating surfaces
has not been reported in all these conditions. Once again, the iden-
tiﬁcation of physiological activators is required not only to under-
stand the activation of factor XII in vivo but also to explain why
activation of the kallikrein–kinin system is not paralleled by acti-
vation of the coagulation system in vivo.
5. The ﬁbrinolytic system
Fibrinolysis is the process that results in the degradation of ﬁ-
brin polymers during the removal of blood clots. This process con-
tributes to wound healing and haemostasis. Similar to the contact
system, it is a proteolytic mechanism that results in the formation
of one main effector enzyme, plasmin, which cleaves ﬁbrin (Fig. 1,
panel d). Plasmin is formed via activation of its liver-produced
zymogen plasminogen by either tissue-type plasminogen activator
(tPA) or urokinase-type plasminogen activator (uPA). tPA, which is
structurally homologous to factor XII (see below), is released by
activated (endothelial) cells in close vicinity of a blood clot. tPA
binds to the ﬁbrin in the blood clot [78], which results in activation
and enhanced cleavage of plasminogen to yield plasmin. Plasmin in
turn also cleaves tPA, which results in an even more active two-
chain tPA. In contrast to tPA, uPA does not directly interact with ﬁ-
brin, but can mediate ﬁbrinolysis when bound to its cellular recep-
tor uPAR. Both plasminogen activators can be inhibited by the
serine-protease inhibitors, such as PAI-1 (plasminogen activator
inhibitor 1), PAI-2 and neuroserpin. The activity of plasmin is
inhibited by plasmin inhibitor, but only when plasmin is not bound
to ﬁbrin.6. Additional activators and roles for tPA in various processes
other than ﬁbrinolysis
Due to its discovery as initiator of ﬁbrinolysis and its activation
by ﬁbrin polymers, tPA and the ﬁbrinolytic system are associated
with the dissolution of blood clots. However, it has been demon-
strated over the years that (1) tPA can be activated by many pro-
teins, (2) plasmin has many substrates other than ﬁbrin and (3)
the ‘ﬁbrinolytic’ system has biological functions independent from
ﬁbrin and separate from its role in blood clot lysis. Examples of
proteins other than ﬁbrin that activate tPA include, extracellular
matrix proteins [79], thrombospondin [80], histidine-proline-rich
glycoprotein [81], maspin [82], actin [83,84], endostatin [85],
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(reviewed in [87]), amyloid-b peptide associated with Alzheimer’s
disease [84,88,89], prion protein of Creutzfeldt-Jakob’s disease
[90], and denatured proteins [91–95]. In addition to polymerized
ﬁbrin in blood clots, also denatured or aggregated forms of its pre-
cursor, ﬁbrinogen, can activate tPA [95,96]. Intriguingly, many acti-
vators of tPA, including ﬁbrin fragments have been demonstrated
to inhibit angiogenesis and may be applicable to treat cancer
[97,98]. Some potential sites in ﬁbrin have been implicated in the
activation of tPA by ﬁbrin [99], but the exact mechanism of activa-
tion by ﬁbrin and by all these other activators remain to be
elucidated.
Plasmin has a broad substrate speciﬁcity and degrades other
extracellular matrix proteins such as laminin. In addition, plasmin
activates pro-collagenases, allowing degradation of collagen, and
plasmin cleaves prohormones, for example latent TGFa. Given
their broad speciﬁcity it seems unlikely that the role of tPA and
plasmin is limited to the dissolution of ﬁbrin in blood clots. Indeed,
both tPA and plasmin have been demonstrated to play a role in
several processes [100], that include tissue remodeling and most
notably, neuronal cell migration and neuronal function, such as
long term potentiation [101].
Studies indicate that tPA modulates the deposition of amyloid-b
peptide that is associated with Alzheimer’s disease [84,102–104].
Plasmin degrades amyloid-b aggregates in vitro [84,104] and amy-
loid-b injected into the brain is not removed in tPA-deﬁcient mice
[103]. Based on these ﬁndings the effects of a PAI-1 inhibitor was
studied in a mouse model of Alzheimer’s disease [102]. This com-
pound, which sustains plasmin activity, enhanced amyloid-b clear-
ance. Thus activation of ﬁbrinolysis may be a novel disease
modifying treatment for amyloidosis. However, tPA can also be
detrimental. In animal models it has been shown that tPA is an
essential element in the induction of excitotoxic injury [105]. As
with the contact system, the ﬁbrinolytic system is implicated in
a large number of pathologies, including amyloidosis, cancer, infec-
tions, atherosclerosis and auto-immune diseases. Another intrigu-
ing overlap between the activation of the contact system by
‘surfaces’ and the activation of the ﬁbrinolytic system is that plas-
minogen plays a central role in the inﬂammatory response to bio-
materials [106].
Taken together, this leads to the central questions: (1) what is
the common denominator among all these different activators of
factor XII and tPA and (2) how do these factors bind to their various
activators. Recent publications have gained insight into these two
questions.7. Misfolded proteins comprise similar features that activate
tPA and factor XII
As described above and in detail elsewhere in this issue and
other reviews proteins can aggregate in multiple ways, resulting
in aggregates with heterogeneous appearances. Also, not all un-
folded proteins will aggregate, be toxic or have an amyloid-like
structure. Aggregates can be amorphous, form oligomers or ﬁbrils.
Within these varieties, common structural and functional proper-
ties have been found, including the propensity to induce cellular
toxicity [10,11]. The details of the structural commonalities in olig-
omers and amorphous aggregates remain to be elucidated, as well
as the exact mechanism(s) responsible for the cellular toxicity. The
current evidence implicates so-called soluble oligomers as the
most toxic species (see other reviews in this issue). Common struc-
tural characteristics of misfolding and subsequent amyloid ﬁbril
formation include the increase in b-sheet content and folding into
the cross-b structure. Such features are directly measured using
circular dichroism (for b-sheet content) and X-ray ﬁbre diffraction(cross-b structure). Alternatively certain dyes, most notably thio-
ﬂavin T (ThT), can be used. Its binding induces ﬂuorescence and
is indicative for structural changes reminiscent to amyloid cross-
b structure. The exact mode of binding of thioﬂavin T remains how-
ever to be established, although recent publications indicate that
thioﬂavin T binds in cavities of the amyloid ﬁbrils [107,108]. Native
proteins do generally not comprise properties common to amyloid
ﬁbrils or their precursors, including afﬁnity for thioﬂavin T and
presence of cross-b structure.
Based on the fact that tPA was activated by numerous proteins,
including denatured proteins and amyloid-b (see above) we
hypothesized that tPA is activated by common features to mis-
folded proteins and demonstrated that tPA is indeed a cross-b
structure receptor [18]. We demonstrated that activation of tPA
correlated with the presence of cross-b structure and is indepen-
dent of the amino acid sequence of the underlying protein
(Fig. 2a). Moreover, the binding of tPA to misfolded proteins com-
prising cross-b structure could be inhibited with Congo red (Bou-
ma, unpublished). Subsequently we established that the
homologous protease, factor XII, is activated by misfolded proteins
as well and that this leads to kallikrein formation but not to activa-
tion of factor XI into XIa [17] (Fig. 2b–d). Activation of factor XII
resulting in kallikrein formation was only observed with misfolded
protein aggregates but not with native, monomeric species nor
with amyloid ﬁbrils. We also demonstrated activation of both the
contact system and the ﬁbrinolytic system in vivo in patients with
systemic amyloidosis [17,109]. In line with the results in vitro,
activation of the kallikrein system was seen in patients with amy-
loidosis, but no activation of factor XI was notable [17]. These ﬁnd-
ings uncovered a possible role for tPA and factor XII in modulating
protein misfolding and protein misfolding diseases.8. Surface-induced conformational changes reminiscent of
misfolding underly the mechanism of activation of the contact
system
In our efforts to elucidate the physiological mechanism of acti-
vation of factor XII we examined the role of protein misfolding in
classical activation of factor XII by surfaces [17]. For a long time
it is known that the contact system is activated by ‘surfaces’ and
that this results in activation of factor XI and prekallikrein. It is also
well known that proteins adsorb to surfaces, such as glass, poly-
mers and also phospholipids. The adsorption of proteins depends
on the molecular weight and with time a low molecular weight
protein is displaced by higher molecular weight proteins. This ef-
fect is known as the Vroman effect and was established with blood
plasma [110]. Many publications have demonstrated that protein
adsorption can result in structural changes and denaturation of
these adsorbed proteins [111,112]. One example includes ﬁbrino-
gen, the precursor protein of ﬁbrin in blood clots, adsorbed to glass
[113]. Recent studies have now also directly demonstrated protein
adsorption to certain materials, including phospholipids [114,115]
and surfaces, like mica [116], with the formation of the structural
features common to misfolded proteins and reminiscent of amy-
loid. In our recent work on the activation of the contact system
we showed that the activation of prekallikrein by factor XII could
not be induced by a ‘surface’ alone, but was completely dependent
on the presence of sufﬁcient amounts of protein [17] (Fig. 2e). We
also demonstrated that the surfaces that induce factor XII activa-
tion through a cofactor protein also induced conformational
changes in these cofactor proteins that likely underly the activa-
tion of factor XII (Fig. 2f). Whereas activation of the kallikrein sys-
tem required addition of proteins (to be denatured by the surface)
activation of factor XI was seen in the absence of proteins (Fig. 2d).
Hence activation of factor XI can be triggered by direct contact of
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Fig. 2. Activation of the ﬁbrinolytic system (tPA) and the kallikrein–kinin system (factor XII) by misfolded proteins. (a) Stimulation of tPA-mediated plasminogen activation
by two forms ovalbumin (OVA), one with (heat denatured OVA, dOVA) and one without amyloid properties (native OVA, nOVA). (b) Factor XII mediated kallikrein generation
induced by misfolded OVA (inset: electronmicroscopic picture of dOVA protein aggregates activating factor XII). (c) Freshly dissolved OVA does not activate factor XII. (d)
Factor XII-dependent activation of factor XI is not stimulated by misfolded proteins (BSA-AGE). (e) Factor XII-dependent kallikrein generation by a surface (shown is kaolin) is
mediated by cofactor proteins. (f) Circular dichroism measurements (near UV spectra) indicate changes in tertiary structure of BSA in the presence of surfaces, kaolin, ellagic
acid (EA) and dextrane sulfate (DXS) that are known activators of factor XII. For additional data and detailed information see [17]. (b–f) are reproduced with permission from
The Journal of Clinical Investigation [17]. BSA-AGE: Bovine serum albumin misfolded through glycation, producing advanced glycation end-products comprising amyloid
properties [135].
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699 2695factor XII to the surface. The mechanism is still unknown, but may
involve conformational changes and autoactivation of factor XII
upon binding to the surface. Such changes have been observed
[117]. A thorough analysis of the literature revealed that in the past
factor XII activation studies were always performed in the pres-
ence of protein in the assay buffer, which explains previously ob-
served kallikrein activation. Recently it was concluded that the
paradigm that negatively charged surfaces activate the contact sys-
tem required substantial revision as also positively charged mate-rials can activate factor XII and that the protein composition of the
ﬂuid plays an important role [118]. Our work has now demon-
strated that the real trigger for activation of factor XII for formation
of kallikrein is the change in protein conformation, i.e. induction of
unfolding and misfolding, due to contact of a native protein with a
non-compatible surface. In this view, the activation of prekallikrein
by factor XII observed in all previous studies should be reconsid-
ered. In these studies the activator of factor XII may in fact be a
protein unfolding (misfolding) inducing agent. Taken together,
2696 M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699our work has changed the view on the activation of factor XII and
revealed insight into the physiological role of the contact system
(see below). These ﬁndings are of particular importance for the
safety of biomaterials, such as stents, and for the manufacturing,
packaging, and storage of biopharmaceuticals [14,15,119]. Hence
tPA and factor XII can be applied as sensitive measurement meth-
ods of biomaterial hemocompatibility and the quality of biophar-
maceuticals [15,120]. This may help to decrease the adverse
inﬂammatory effects of biomaterials, such as hemodialysis systems
or stents, and the immunogenicity of biopharmaceuticals.9. The ﬁbronectin type I domain (‘ﬁnger domain’) – a motif that
binds misfolded proteins
How do factor XII and tPA recognize their activators, i.e. mis-
folded proteins. These proteases are quite homologous and com-
prise several distinct motifs (Fig. 3). Using deletion mutants and
recombinantly produced domains we recently mapped the binding
site to the ﬁbronectin type I (or ‘ﬁnger’) domain [121]. We also
found that similar domains in yet another homologous protein,
hepatocyte growth factor activator (HGFA) and in the extracellular
matrix protein ﬁbronectin bind protein aggregates. We demon-
strated that isolated ﬁbronectin type I domains can inhibit platelet
aggregation induced by misfolded protein aggregates, which may
offer new therapeutic strategies to treat diseases associated with
protein misfolding. The same domains were previously shown to
mediate the interaction of tPA with ﬁbrin [78,122] and ﬁbronectin
with ﬁbrin [123]. This suggests that the interaction of tPA with
misfolded proteins and ﬁbrin may result from common structural
features. Hence, does ﬁbrin has amyloid-like properties?10. What about misfolding properties in ﬁbrin?
Some speciﬁc amino acid sequences in ﬁbrin have been identi-
ﬁed to induce tPA activation [124]. However, the evidence has been
gathered with the use of synthetic peptides. We showed, at least
for one peptide (amino acid 148–160 of the alpha-chain of ﬁbrin
(ogen), that, while the crystal structure predicts the formation ofFig. 3. Schematic representation of the structure of factor XII, tPA, HGFA and ﬁbronectin
and ﬁbronectin. F, ﬁbronectin type I (‘ﬁnger’) domain; E, EGF-like domain; II, ﬁbronectin
protease domain.a-helix, these peptides form cross-b structure in vitro [18]. At pres-
ent it is widely accepted that the structural changes leading to the
exposure of sites thought to bind t-PA and/or plasminogen remain
to be demonstrated [125]. We studied structural properties of ﬁ-
brin and found that ﬁbrin has structural properties reminiscent
of amyloid (Bouma, manuscript submitted). Thrombin-induced
polymerized ﬁbrin binds the amyloid dyes, Congo red and thioﬂa-
vin T. Fibrin also binds serum amyloid P (SAP), a protein used to
diagnose amyloidosis also in vivo [126]. Finally we demonstrated
the presence of cross-b structure using X-ray ﬁbre diffraction anal-
ysis. Our results ﬁt with early data on the structural changes that
are associated with the conversion of ﬁbrinogen into ﬁbrin that
showed that ﬁbrin formation is accompanied by a general increase
in b-sheet formation of hydrogen bonds between adjacent ﬁbrin
molecules [127]. This type of interaction within the ﬁbrin mesh-
work is similar to that underlying the cross-b structure in amyloid,
suggesting that these cross-b structures are formed during ﬁbrin
polymerization. Hence, this common structural element, which
can be formed by a myriad of proteins including ﬁbrin, triggers
ﬁbrinolysis, contributing to the removal of obsolete proteins, such
as ﬁbrin in blood clots, and potentially also all other proteins. Just
recently, it was shown that ﬁbrin also activates factor XII [128],
supporting the idea that a common structural element is present
in ﬁbrin and protein aggregates to activate both tPA and factor XII.11. The Crossbeta pathway: new roles for two old factors
Together, new roles have been identiﬁed for two old factors:
factor XII and tPA. We have shown that both the contact system
and the ﬁbrinolytic system react to misfolded proteins of various
origin. Activation of factor XII by misfolded proteins leads to kalli-
krein and BK formation but not to factor XIa generation. This im-
plies that in this situation the intrinsic pathway of coagulation is
not triggered but that instead a fast vasoactive and proinﬂamma-
tory response is the result. The ﬁbrinolytic system is also activated
because BK induces the release of tPA from endothelial cells while
kallikrein activates both urokinase-type plasminogen activator and
plasminogen. Earlier, we reported that tPA-dependent plasmin for-. Domain architecture of tPA, factor XII, hepatocyte growth factor activator (HGFA)
type II domain; III, ﬁbronectin type III domain; Pr, proline-rich region; K, Kringle; P,
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grades ﬁbrin clots but also plays a role in inﬂammation and wound
repair. Evidence for the generation of kallikrein but not FXIa and
activation of the ﬁbrinolytic system was obtained in patients with
systemic amyloidosis. Activation of factor XII resulting in kallikrein
formation was only observed with misfolded protein aggregates
but not with native, monomeric species or amyloid ﬁbrils. The pro-
tein aggregates resemble preﬁbrillar, oligomeric species that are
held responsible for the toxicity seen in protein misfolding disease.
We therefore propose that the contact system and the ﬁbrinolytic
system contribute under normal conditions to the detection and
removal of otherwise potential harmful protein aggregates, before
they become protease resistant amyloid ﬁbrils. As mentioned
above activation of the contact system was observed in a wide
variety of diseases i.e. diabetic retinopathy, lactic acidosis and
inﬂammatory bowel disease. It is tempting to speculate that in
these conditions for instance changes in pH have led to the forma-
tion of misfolded proteins and as a consequence activation of factor
XII. Since misfolded proteins can be formed under a variety of con-
ditions (e.g. pH, temperature, oxidative stress, ﬂow stress, glyca-
tion) and by a large number of ‘‘denaturing” compounds and
materials (e.g. glass, lipids, endothelial associated glycosaminogly-
cans, RNA) it is anticipated that protein aggregation is much more
wide spread than currently known. For example, protein aggrega-
tion may underly pathological conditions with at present unknown
etiology in which factor XII activation has been implicated, i.e.
auto-immune disease such as those associated with the use of bio-
pharmaceuticals or the anaphylactic reactions observed with cer-
tain preparations of heparin that were contaminated with
oversulfated chondroitin sulfate [129,130].
Unfolding of proteins is a fact of nature. We propose that with
the identiﬁcation of tPA and factor XII we have uncovered an an-
cient pathway for the clearance of unfolded proteins that facilitates
protein homeostasis and prevents against protein misfolding dis-
eases. This ﬁts well with the suggested protective role for factor
XII [55]. The complement system and certain scavenger receptors,
like the receptor for advanced glycation end-products RAGE
[131,132], CD36 [133] and LRP [134] that were also shown to bind
certain amyloids are likely part of this pathway. We have termed
this clearance mechanism for obsolete proteins the ‘cross-b path-
way’ [135] (Fig. 4). Modulating the cross-b pathway is an attractive
strategy for the treatment of protein misfolding diseases, which are
mostly highly debilitating and currently untreatable.Fig. 4. Scheme of Crossbeta pathway with the new role for the contact and
ﬁbrinolytic system. FX, factor XII; BK, bradykinin; Plm, plasmin.Conﬂict of interest
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